CDI results from disruption of normal, healthy bacteria in the colon, often as a result of antibiotics.
IMM-529 is a biological product which is intended to prevent and treat CDI without destroying the microbiome like antibiotic treatments, allowing the microbiome to return to a healthy state.
The antibodies survive transit through the stomach and remain functional in the large intestine.
IMM-529 was manufactured by the Commonwealth Scientific and Industrial Research Organisation (CSIRO) Separations Science team and Pharmaceutical Packaging Professionals.
Human safety and efficacy studies (Phase 1/2 clinical trial) of IMM-529 will start by the end of Q2 2017, and will aim to build on positive pre-clinical results.
These results were reported from a series of proof-of-concept efficacy studies completed by Dr. Dena Lyras and her research team at the Monash University in Melbourne.
CDI has become a major-medical problem causing an estimated annual economic cost of more than US$10 billion globally.
The problem is especially acute in hospitals and in long-term in-patient care facilities.
Immuron’s share price has more than doubled since the start of 2017, last trading at $0.55.